Código 3822 (Harmonized System 2012 by 4 digits)
2023: US$1.06B, Total Trade Exchange
2023: US$255M, International Sales
2023: US$808M, International Purchases
In 2023, the trade exchange (includes international purchases and sales) of Diagnostic or Laboratory Reagents on a Backing and Prepared Diagnostic, other than those of Heading No. 3002 or 3006 was US$1.06B.
In 2023, the states with the most international sales in Diagnostic or Laboratory Reagents on a Backing and Prepared Diagnostic, other than those of Heading No. 3002 or 3006 were Baja California (US$138M), Chihuahua (US$113M), Ciudad de México (US$1.94M), Tamaulipas (US$980k), and Estado de México (US$611k).
The states with the most international purchases in 2023 were Ciudad de México (US$490M), Chihuahua (US$114M), Baja California (US$73.5M), Estado de México (US$47.4M), and Nuevo León (US$40.6M).
In 2023, the main commercial destinations of Diagnostic or Laboratory Reagents on a Backing and Prepared Diagnostic, other than those of Heading No. 3002 or 3006 were United States (US$249M), Canada (US$3.55M), Costa Rica (US$621k), Cuba (US$394k), and Guatemala (US$228k).
The main commercial origins of Diagnostic or Laboratory Reagents on a Backing and Prepared Diagnostic, other than those of Heading No. 3002 or 3006 in 2023 were United States (US$317M), China (US$144M), Germany (US$130M), United Kingdom (US$45.4M), and Spain (US$23.2M).
In the global context, the main exporting countries of Diagnostic or Laboratory Reagents on a Backing and Prepared Diagnostic, other than those of Heading No. 3002 or 3006 in 2022 were China (US$13.3B), United States (US$12.4B), and Germany (US$7.39B). In the same year, the main importing countries of Diagnostic or Laboratory Reagents on a Backing and Prepared Diagnostic, other than those of Heading No. 3002 or 3006 were United States (US$9.17B), Germany (US$6.21B), and China (US$3.87B).
US$1.06B, Total Trade Exchange (2023)
In 2023, the total trade exchange of Diagnostic or Laboratory Reagents on a Backing and Prepared Diagnostic, other than those of Heading No. 3002 or 3006 in Mexico (including international purchases and sales) was US$1.06B.
The visualizations show the net balance of Diagnostic or Laboratory Reagents on a Backing and Prepared Diagnostic, other than those of Heading No. 3002 or 3006 at the level of states and countries. Colors more similar to blue, indicate that the territory presented a higher level of international sales. Colors more similar to red, indicate that the territory presented a higher level of international purchases.
February, 2023
In February 2023, international sales of Diagnostic or Laboratory Reagents on a Backing and Prepared Diagnostic, other than those of Heading No. 3002 or 3006 were US$21.6M, while international purchases reached US$61.9M. The above results in a trade balance of -US$40.3M.
2023-Q1: US$54.7M, International Sales
The visualization shows the quarterly concentration of international sales of Diagnostic or Laboratory Reagents on a Backing and Prepared Diagnostic, other than those of Heading No. 3002 or 3006 at state level.
In the first quarter of 2023, international sales were US$54.7M, being the states with the most sales Baja California (US$33.7M), Chihuahua (US$20.4M), and Ciudad de México (US$330k).
Baja California: US$138M, State with the Most International Sales (2023)
United States: US$249M, Main commercial destination (2023)
In 2023, the states with the highest international sales in Diagnostic or Laboratory Reagents on a Backing and Prepared Diagnostic, other than those of Heading No. 3002 or 3006 were Baja California (US$138M), Chihuahua (US$113M), Ciudad de México (US$1.94M), Tamaulipas (US$980k), and Estado de México (US$611k).
In 2023, the countries with the most international purchases from Mexico were United States (US$249M), Canada (US$3.55M), Costa Rica (US$621k), Cuba (US$394k), and Guatemala (US$228k).
Ciudad de México: US$490M, State with the Most International Purchases (2023)
United States: US$317M, Main Commercial Origin (2023)
In 2023, the states with the highest international in Diagnostic or Laboratory Reagents on a Backing and Prepared Diagnostic, other than those of Heading No. 3002 or 3006 were Ciudad de México (US$490M), Chihuahua (US$114M), Baja California (US$73.5M), Estado de México (US$47.4M), and Nuevo León (US$40.6M).
The countries with the most international sales to Mexico in 2023 were United States (US$317M), China (US$144M), Germany (US$130M), United Kingdom (US$45.4M), and Spain (US$23.2M).
The RCA-Complexity diagram compares the Revelead Comparative Advantages of states in Diagnostic or Laboratory Reagents on a Backing and Prepared Diagnostic, other than those of Heading No. 3002 or 3006 and the Economic Complexity Index of each state.
RCA values greater than 1 indicate that the state has comparative advantages in Diagnostic or Laboratory Reagents on a Backing and Prepared Diagnostic, other than those of Heading No. 3002 or 3006. On the other hand, high levels of complexity (ECI) are associated with higher levels of income, potential for economic growth, lower income inequality and lower emissions.
The visualizations show the global market for Diagnostic or Laboratory Reagents on a Backing and Prepared Diagnostic, other than those of Heading No. 3002 or 3006. In both charts, Mexico stands out in order to identify its participation in the export and import market.
In 2022, the main exporting countries of Diagnostic or Laboratory Reagents on a Backing and Prepared Diagnostic, other than those of Heading No. 3002 or 3006 were China (US$13.3B), United States (US$12.4B), and Germany (US$7.39B). In the same year, the main importing countries for Diagnostic or Laboratory Reagents on a Backing and Prepared Diagnostic, other than those of Heading No. 3002 or 3006 were United States (US$9.17B), Germany (US$6.21B), and China (US$3.87B).